Clinical Trial Update: A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial updating on Codrituzumab for children and young adults with primary extracranial solid tumors or recurrent/refractory GPC3-expressing t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extracranial Solid Tumor

Drugs mentioned

• Codrituzumab (codrituzumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) | Phase 1 | Status: RECRUITING